Generic Manufacturers’ Labeling Catch-22

Show full item record

Title: Generic Manufacturers’ Labeling Catch-22
Author: Lee, Stacey
Abstract: In Wyeth v. Levine, the Supreme Court eliminated brand-name manufacturers’ ability to use the preemption defense against state law failure to warn claims involving allegedly misbranded pharmaceutical drugs. Since that time, a heated debate has ensued among federal courts and legal scholars regarding that holding’s effect on generic manufacturers. Lost amid these judicial opinions and scholarly articles, however, is a more fundamental inquiry. Regardless of whether preemption is a viable defense, what type of legal and regulatory framework is needed to ensure generic manufacturers possess the necessary tools to fulfill their responsibility of providing consumers and the medical community with current and accurate labeling instructions for their products? This Article proposes such a framework.
Date: 2011
Subject: K2
Generics, Preemption, Drug Labeling Regulatory Framework
Series: Teh Johns Hopkins Carey Business school Working Paper Series;11-03-001

Files in this item

Files Size Format Download
SBLee Catch-22.pdf 565.5Kb application/pdf Download

The following license files are associated with this item:

This item appears in the following Collection(s)

Show full item record